What's new at the NMI? What is happening at the NMI and in the research landscape?Find out more about the NMI!
The NMI Natural and Medical Sciences Institute at the University of Tübingen is focusing its research efforts into infections with the novel coronavirus (SARS-CoV-2).
Together with Proteona and Synovo, the NMI will use its platform for patient-derived microtumours for drug screening and the discovery of potential drug candidates.
In order to protect individuals as well as society as a whole, the NMI has also taken measures to protect employees in the light of the corona pandemic.
In cooperation with the medical technology company Joline, in the future the NMI will conduct research on central venous catheters that have an antibacterial effect due to their water-loving surface. A positive side effect: the researchers expect that the new surface will also significantly reduce the risk of thrombosis.
After the NMI and the Karlsruhe Institute of Technology (KIT) have already worked on joint projects in the past, a long-term cooperation will now be sealed by a cooperation agreement.
Last week, the NMI, represented by Prof. Katja Schenke-Layland, Dr. Stefan Raible, Dr. Hanna Hartmann and Dr.-Ing René von Metzen, travelled to Nancy, France, to participate in the German-French Forum.
After Prof. Katja Schenke-Layland had already attended the "forum gesundheitsstandort BW" in October 2019 as spokesperson for the subject area of business-oriented research, innovations and value creation in the healthcare industry, she travelled to Brussels together with Winfried Kretschmann on 21 January 2020.
Innovative strength and NMI - these are two terms that complement each other perfectly, not only in our opinion. For that reason, the Chamber of Industry and Commerce Reutlingen invited Katja Schenke-Layland to a panel discussion ...
Nicole Schneiderhan-Marra will be representing the NMI with a talk.
Scientists from the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation dedicated to applied and translational research, and of contract research provider NMI TT Pharmaservices, announced two publication.
Thomas Joos will be representing the NMI at Barcelona.